阿帕替尼联合紫杉醇单药化疗对复发性铂类耐药型卵巢癌患者的临床疗效分析  

Analysis of the clinical efficacy of apatinib combined with paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer

作　　者：闫静 和光宇 YAN Jing;HE Guang-yu(Traditional Chinese Medicine Hospital of Shanxian County,Heze 274300,China)

机构地区：[1]山东省单县中医医院,274300 [2]山东省单县中心医院,274300

出　　处：《中国实用医药》2022年第4期133-135,共3页China Practical Medicine

摘　　要：目的探讨阿帕替尼联合紫杉醇单药化疗对复发性铂类耐药型卵巢癌患者的治疗效果。方法74例复发性铂类耐药型卵巢癌患者,随机分为观察组和对照组,每组37例。观察组采取阿帕替尼联合紫杉醇单药化疗,对照组采取传统紫杉醇单药化疗。比较两组患者的治疗效果、不良反应发生情况。结果观察组客观缓解率为67.57%,高于对照组的43.24%,差异具有统计学意义(P<0.05)。观察组不良反应发生率为16.22%,低于对照组的40.54%,差异具有统计学意义(P<0.05)。结论在对复发性铂类耐药型卵巢癌患者进行治疗时,采用阿帕替尼联合紫杉醇单药化疗治疗方法,能够提升患者治疗效果,改善患者的病情,且安全性较高,值得临床推广应用。Objective To discuss the therapeutic effect of apatinib combined with paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.Methods A total of 74 patients with recurrent platinum-resistant ovarian cancer were randomly divided into observation group and control group,with 37 cases in each group.The observation group was treated with apatinib in combination with paclitaxel monotherapy,and the control group was treated with traditional paclitaxel monotherapy.The therapeutic effect and occurrence of adverse reactions of the two groups were compared.Results The objective response rate in the observation group was 67.57%,which was higher than 43.24%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 16.22%,which was lower than 40.54%in the control group,and the difference was statistically significant(P<0.05).Conclusion In the treatment of patients with recurrent platinum-resistant ovarian cancer,the use of apatinib in combination with paclitaxel monotherapy treatment can enhance the therapeutic effect and improve the patient’s condition with high safety,which is worthy of clinical promotion and application.

关 键 词：阿帕替尼 紫杉醇单药化疗 铂类耐药型卵巢癌 复发 

分 类 号：R737.31[医药卫生—肿瘤]